Erratum: Metabolic Effects of Paliperidone Extended Release Versus Oral Olanzapine in Patients With SchizophreniaA Prospective, Randomized, Controlled Trial
The authors notified us of two errors they missed in proofs in “Metabolic Effects of Paliperidone Extended Release Versus Oral Olanzapine in Patients With Schizophrenia: A Prospective, Randomized, Controlled Trial” their article in the August 2012 issue of the Journal of Clinical Psychopharmacology (J Clin Psychopharmacology. 2012;32:449–457).
Abstract (page 449, line 16) and Results (page 452, 3rd paragraph, line 6): The numbers “0.097 ± 2.72” should be “0.97 ± 2.72”.
On page 450, first paragraph, line 8: The words “paliperidone ER” should be “paliperidone palmitate” to say: “A 13-week, double-blind, head-to-head, comparative trial of paliperidone palmitate versus risperidone long-acting injectable in adults with schizophrenia showed similar efficacy and tolerability with both treatments,…”.
© 2012 Lippincott Williams & Wilkins, Inc.
Schreiner A, Niehaus D, Shuriquie NA, et al. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial. J Clin Psychopharmacology
. 2012; 32:449–457.